ArticleHealth affairs (Project Hope)
Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.
Article in Health affairs (Project Hope). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03640234 (Return of Actionable Variants Empirical), which is not on this map. Cited by 63 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Return of Actionable Variants Empirical (RAVE) Study
Who cites it
63 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.Alzheimer's research & therapy · 2016Pooled it
- Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.Genetics in medicine : official journal of the American College of Medical Genetics · 2011Guideline
- Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours.The Cochrane database of systematic reviews · 2010Pooled it
- The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop.Genetics in medicine : official journal of the American College of Medical Genetics · 2009Guideline
- Psychological impacts of APOE genotype disclosure among Latinos in New York City: a randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.The journal of prevention of Alzheimer's disease · 2024Trial
- The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine.Trials · 2014Trial
- Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility.Genetic testing and molecular biomarkers · 2011Trial
- Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease.Journal of health communication · 2009Trial
- Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2008Trial
- Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.Alzheimer disease and associated disordersTrial
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges.The journal of prevention of Alzheimer's disease · 2025Review
- Planning for the future following receipt of Alzheimer's disease risk estimate among Latinos in New York City.Journal of Alzheimer's disease : JAD · 2025Article
- Potential corporate uses of polygenic indexes: Starting a conversation about the associated ethics and policy issues.American journal of human genetics · 2024Article
- Direct to Consumer Biomarker Testing for Alzheimer Disease-Are We Ready for the Insurance Consequences?JAMA neurology · 2024Article
- What Can Economics Say about Alzheimer's Disease?Journal of economic literature · 2023Article
- Comparison of intact protein and digested peptide techniques for high throughput proteotyping of ApoE.Clinical proteomics · 2022Article
- Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?Therapeutic advances in chronic disease · 2022Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
New genetic tests for adult-onset diseases raise concerns about possible adverse selection in insurance markets. To test for this behavior, we followed 148 cognitively normal people participating in a randomized clinical trial of genetic testing for Alzheimer's disease for one year after risk assessment and Apolipoprotein E (APOE) genotype disclosure. Although no significant differences were found in health, life, or disability insurance purchases, those who tested positive were 5.76 times more likely to have altered their long-term care insurance than those who did not receive APOE genotype disclosure. If genetic testing for Alzheimer's risk assessment becomes common, it could trigger adverse selection in long-term care insurance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.